COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

The Effectiveness of Intravitreal Avastin Injection for CRVO

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01678248
Recruitment Status : Unknown
Verified August 2012 by Ziv Hospital.
Recruitment status was:  Recruiting
First Posted : September 3, 2012
Last Update Posted : September 3, 2012
Information provided by (Responsible Party):
Ziv Hospital

Brief Summary:
to determine the effectivness of intravitreal avastin injection on visual acuity on people that suffer from central retinal vein occlusion

Condition or disease
Central Retinal Vein Occlusion

Layout table for study information
Study Type : Observational
Estimated Enrollment : 68 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: The Effectiveness of Intravitreal Avastin Injection for CRVO
Study Start Date : January 2006

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
patients who suffer from CRVO and were injected by bevazicumab intravitrealy

Inclusion Criteria:

  • patients above 18 years old
  • suffer from CRVO
  • maximal visual acuity 6/15

Exclusion Criteria:

  • VA of LP
  • retinal disease other than CRVO
  • incomplete medical record
  • follow up less than 6 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01678248

Layout table for location contacts
Contact: Joseph pikkel, M.D 972508434206
Contact: Otzem Chassid, M.D 972506266059

Layout table for location information
Ziv Medical Center Recruiting
Safed, Israel, 13100
Contact: Otzem Chassid, M.D   
Principal Investigator: Joseph Pikkel, M.D         
Sponsors and Collaborators
Ziv Hospital

Layout table for additonal information
Responsible Party: Ziv Hospital Identifier: NCT01678248    
Other Study ID Numbers: 0048-12-ZIV
First Posted: September 3, 2012    Key Record Dates
Last Update Posted: September 3, 2012
Last Verified: August 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Retinal Vein Occlusion
Retinal Diseases
Eye Diseases
Venous Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors